Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Share:
Related BMY
Bristol-Myers Stock May Have Exhausted Its Upside For Now
Benzinga's Top Upgrades, Downgrades For October 16, 2017
Sabal Trust CO Buys United Parcel Service Inc, Bristol-Myers Squibb Company, Hanesbrands Inc, ... (GuruFocus)
Related MRK
Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback
Bank Of America Sees NewLink Genetics As 'Undervalued'
Inverness Counsel Inc Buys CVS Health Corp, JPMorgan Chase, Corning Inc, Sells Dover Corp, ... (GuruFocus)

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2017JefferiesDowngradesBuyHold
Oct 2017BarclaysMaintainsEqual-Weight
Oct 2017UBSMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...